Affilogic is a private biotech company specialized in discovering and developing Nanofitins®-based therapeutics, through in house programs or collaborations with worldwide industry leaders in the pharmaceutical sector.
Recent news :
Aug 2025 – Affilogic’s CEO Presenting latest data generated on our ODC program : Olivier Kitten is presenting at next Immuno-Oncology Summit 2025 latest in-vivo data on our ODC program, showing anti-tumor effect in xenografted mice.
Apr 2025 – Affilogic’s Partner Bracco Imaging published Nanofitins data in Nature Scientific Report : Bracco Imaging has published new data using HER-2 targeting Nanofitins used as diagnostic tool for the management of HER-2 positive tumors.
Around the world
Immuno-Oncology Summit 2025
Affilogic’s CEO Olivier Kitten will present at Immuno-Oncology Summit 2025 Philadelphia – USA
Aug 11-13, 2025
BIO International 2025
Affilogic will attend BIO International 2025 in Boston – USA
Jun 16-19, 2025
ASCO 2025
Affilogic will attend ASCO 2025 in Chicago – USA
May 30- Jun 03, 2025
Nanofitins
Each Nanofitin® is 20 times smaller than an antibody and demonstrates hyper stability. Their simple protein scaffold is particularly fitted for combination.
Read More
Our Programs
Affilogic develops therapeutic programs leveraging unique Nanofitins’ properties for brain delivery, inhalation of antivirals, oral GI treatments or small size drug conjugates.
Read More
NanoVector
Affilogic works with partners to deliver their therapeutic compounds to specific cells / organs with existing Nanofitins® or through custom generation of Nanofitins®.
Read More